2. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

kynurenine pathway

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

7

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W001171
    3-Hydroxyanthranilic acid
    1 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases .
    3-Hydroxyanthranilic acid
  • HY-33298
    LM10
    1 Publications Verification

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    LM10 is a potent inhibitor of tryptophan 2,3-dioxygenase (TDO). Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. LM10 has the potential for the research of cancer diseases .
    LM10
  • HY-W011417
    Cinnabarinic acid
    1 Publications Verification

    		 Endogenous Metabolite mGluR Apoptosis Others
    Cinnabarinic acid is a specific orthosteric agonist of mGlu4 by interacting with residues of the glutamate binding pocket of mGlu4, has no activity at other mGlu receptors. Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway of tryptophan. Cinnabarinic acid induces cell apoptosis .
    Cinnabarinic acid
  • HY-151108
    IDO1/TDO-IN-4
    1 Publications Verification

    		 Indoleamine 2,3-Dioxygenase (IDO) Neurological Disease Inflammation/Immunology
    IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders .
    IDO1/TDO-IN-4
  • HY-N1939
    Icariside I
    3 Publications Verification

    Icarisid I

    		 Apoptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) STAT CDK Bcl-2 Family Aryl Hydrocarbon Receptor JAK Caspase IFNAR PD-1/PD-L1 Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape .
    Icariside I
  • HY-133677
    Mono(2-ethyl-5-hydroxyhexyl) phthalate

    MEHHP

    		 Drug Metabolite Apoptosis Aryl Hydrocarbon Receptor Cancer
    Mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) is a biomarker for human exposure to DEHP (HY-B1945). By activating the tryptophan-kynurenine-aryl hydrocarbon receptor (AhR) pathway, mono (2-ethyl-5-hydroxyhexyl) phthalate significantly increases the viability of primary uterine leiomyoma cells and reduces cell apoptosis. Mono (2-ethyl-5-hydroxyhexyl) phthalate correlates with decreased sperm DNA damage. Mono (2-ethyl-5-hydroxyhexyl) phthalate can be used in studies related to uterine leiomyoma .
    Mono(2-ethyl-5-hydroxyhexyl) phthalate
  • HY-112179
    GSK180
    2 Publications Verification

    		 KMO Inflammation/Immunology
    GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition .
    GSK180
  • HY-W014504
    DL-Kynurenine

    		Endogenous Metabolite Metabolic Disease
    DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity .
    DL-Kynurenine
  • HY-W011417R
    Cinnabarinic acid (Standard)

    		Endogenous Metabolite Reference Standards mGluR Apoptosis Others
    Cinnabarinic acid (Standard) is the analytical standard of Cinnabarinic acid. This product is intended for research and analytical applications. Cinnabarinic acid is a specific orthosteric agonist of mGlu4 by interacting with residues of the glutamate binding pocket of mGlu4, has no activity at other mGlu receptors. Cinnabarinic acid is an endogenous metabolite of the kynurenine pathway of tryptophan. Cinnabarinic acid induces cell apoptosis .
    Cinnabarinic acid (Standard)
  • HY-W001171R
    3-Hydroxyanthranilic acid (Standard)
    1 Publications Verification

    		 Reference Standards Endogenous Metabolite Others
    3-Hydroxyanthranilic acid (Standard) is the analytical standard of 3-Hydroxyanthranilic acid. This product is intended for research and analytical applications. 3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.
    3-Hydroxyanthranilic acid (Standard)
  • HY-W654331
    Quinolinic acid-13C3, 15N

    2,3-Pyridinedicarboxylic Acid-13C3,15N

    		 Isotope-Labeled Compounds iGluR Endogenous Metabolite Inflammation/Immunology
    Quinolinic acid- 13C3, 15N (2,3-Pyridinedicarboxylic Acid- 13C3, 15N) is the 13C- and 15N-labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .
    Quinolinic acid-13C3, 15N
  • HY-133677S
    Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4

    MEHHP-d4

    		 Isotope-Labeled Compounds Drug Metabolite Apoptosis Aryl Hydrocarbon Receptor Cancer
    Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4 (MEHHP-d4) is a deuterium labeled Mono(2-ethyl-5-hydroxyhexyl) phthalate (HY-133677). Mono (2-ethyl-5-hydroxyhexyl) phthalate is a biomarker for human exposure to DEHP (HY-B1945). By activating the tryptophan-kynurenine-aryl hydrocarbon receptor (AhR) pathway, mono (2-ethyl-5-hydroxyhexyl) phthalate significantly increases the viability of primary uterine leiomyoma cells and reduces cell apoptosis. Mono (2-ethyl-5-hydroxyhexyl) phthalate correlates with decreased sperm DNA damage. Mono (2-ethyl-5-hydroxyhexyl) phthalate can be used in studies related to uterine leiomyoma.
    Mono(2-ethyl-5-hydroxyhexyl) phthalate-d4
  • HY-W014504S1
    DL-Kynurenine-d7

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    DL-Kynurenine-d7 is the deuterium labeled DL-Kynurenine. DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity.
    DL-Kynurenine-d7
  • HY-W014504R
    DL-Kynurenine (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    DL-Kynurenine (Standard) is the analytical standard of DL-Kynurenine. This product is intended for research and analytical applications. DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity.
    DL-Kynurenine (Standard)
  • HY-173513
    IDO1/TDO-IN-8

    		Indoleamine 2,3-Dioxygenase (IDO) Neurological Disease
    IDO1/TDO-IN-8 (Compound CZ-17) is a dual IDO1 and TDO inhibitor that can penetrate the blood-brain barrier, with EC50 values of 0.33 μM and 1.78 μM, respectively. IDO1/TDO-IN-8 reduces the kynurenine/tryptophan ratio by regulating the kynurenine pathway of tryptophan metabolism. IDO1/TDO-IN-8 has a neuroprotective effect and can alleviate motor dysfunction and improve depressive behavior. IDO1/TDO-IN-8 can be used in the study of Parkinson's disease combined with depression .
    IDO1/TDO-IN-8
  • HY-146261
    HI5

    		Microtubule/Tubulin Indoleamine 2,3-Dioxygenase (IDO) Apoptosis Cancer
    HI5 is a potent tublin and IDO inhibitor, with an IC50 value of 70 nM in HeLa cells. HI5 inhibit IDO expression and decrease kynurenine production, leading to stimulating T cells activation and proliferation. HI5 can inhibit tubulin polymerization and cell migration, cause G2/M phase arrest, and induce apoptosis via the mitochondrial dependent apoptosis pathway and cause reactive oxidative stress generation in HeLa cells. HI5 can be used for researching anticancer .
    HI5
  • HY-N1939R
    Icariside I (Standard)

    Icarisid I (Standard)

    		 Reference Standards Apoptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) STAT CDK Bcl-2 Family Aryl Hydrocarbon Receptor JAK Caspase IFNAR PD-1/PD-L1 Inflammation/Immunology Endocrinology Cancer
    Icariside I (Standard) is the analytical standard of Icariside I (HY-N1939). This product is intended for research and analytical applications. Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP (HY-B2176) or Nigericin (HY-127019)-induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape .
    Icariside I (Standard)
  • HY-183317
    IDO1-IN-34

    		Indoleamine 2,3-Dioxygenase (IDO) Interleukin Related Apoptosis Caspase PARP Cancer
    IDO1-IN-34 is a selective IDO1 inhibitor with an IC50 of 0.093 μM. IDO1-IN-34 exhibits cytotoxicity against various cancer cell lines. IDO1-IN-34 inhibits the kynurenine (kynurenine) pathway and activates IL-2. IDO1-IN-34 induces cell apoptosis via the endogenous mitochondrial pathway, while increasing the levels of cytochrome c, caspase-3, caspase-9 and PARP-1. IDO1-IN-34 can be used for research on liver cancer, lung cancer, breast cancer, prostate cancer, colon cancer and leukemia .
    IDO1-IN-34
  • HY-182456
    CHDI-340246

    		KMO Neurological Disease
    CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease .
    CHDI-340246
  • HY-184134
    IDO1/TDO-IN-16

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-16 (Fig.1 Compound 4) is a dual inhibitor of IDO1 and TDO. IDO1/TDO-IN-16 is applicable for cancer research .
    IDO1/TDO-IN-16
  • HY-N19001
    (rac)-5-Hydroxykynurenine

    		Drug Metabolite Metabolic Disease
    (rac)-5-Hydroxykynurenine is a urinary metabolite. (rac)-5-Hydroxykynurenine is generated via indole ring oxidative cleavage of 5-hydroxytryptophan (HY-N0122) catalyzed by indoleamine 2,3-dioxygenase .
    (rac)-5-Hydroxykynurenine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: